Max Lataillade VP Head of global Research Strategy, is responsible for global research and development strategy for the HIV pipeline at ViiV Healthcare, the only company 100% dedicated to HIV. He oversees end-to-end R&D activities for all novel HIV pipeline programs designed to address key unmet medical needs for people living with HIV. Max ultimately is accountable for several dedicated and diverse teams and leads several programs with a focused approach on developing new antiretroviral agents that are safe and well tolerated with novel mechanisms of action for the treatment, prevention, and ultimately cure of HIV. Prior to joining ViiV Healthcare, Max was VP and Head of Global Development for HIV at Bristol-Myers Squibb where he joined the global clinical research group in 2007 as an infectious disease and HIV specialist from Yale University.
Max obtained his medical degree from the University of Medicine and Dentistry New Jersey, completed his medical residency training at Temple University and Crozer-Chester Medical Center in Philadelphia in 2004, and finished his fellowship in Infectious Diseases and HIV at Yale University School of Medicine in 2007. Max is still a practicing physician with a very diversified practice. He is an assistant professor and teaching attending at Yale, and still volunteers at the West Haven VA HIV clinic in Connecticut.